Clinical relevance of colorectal cancer molecular subtypes

被引：105

作者：

Rodriguez-Salas, Nuria ^{[1
]}

Dominguez, Gema ^{[2
]}

Barderas, Rodrigo ^{[3
]}

Mendiola, Marta ^{[4
]}

Garcia-Albeniz, Xabier ^{[5
,6
]}

Maurel, Juan ^{[7
]}

Feliu Batlle, Jaime ^{[1
,8
]}

机构：

[1] Univ Autonoma Madrid, La Paz Univ Hosp, Dept Med Oncol, Paseo La Castellana 261, Madrid 28046, Spain

[2] CSIC UAM, Inst Invest Biomed Alberto Sols, Sch Med, Dept Med, Calle Arturo Duperier 4, Madrid 28029, Spain

[3] Univ Complutense Madrid, Fac Ciencias Quim, Biochem & Mol Biol Dept, E-28040 Madrid, Spain

[4] La Paz Hosp Res Inst IdiPAZ, Mol Pathol Canc & Therapeut Targets Grp, Paseo La Castellana 261, Madrid 28046, Spain

[5] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

[6] Massachusetts Gen Hosp, Mongan Inst, Boston, MA USA

[7] Univ Barcelona, Hosp Clin Barcelona, Translat Genom & Targeted Therapeut Solid Tumors, IDIBAPS,Dept Med Oncol, Barcelona, Spain

[8] Inst Salud Carlos III, CIBER Canc, Madrid, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2017年 / 109卷

关键词：

Colorectal cancer; Molecular subtypes; Personalized treatment; III COLON-CANCER; ISLAND METHYLATOR PHENOTYPE; MISMATCH REPAIR STATUS; MICROSATELLITE-INSTABILITY; STAGE-II; GENE-MUTATIONS; ADJUVANT THERAPY; POOR-PROGNOSIS; BRAF MUTATION; RAS;

D O I：

10.1016/j.critrevonc.2016.11.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer (CRC) is characterized by alteration of critical pathways such TP53 inactivation, BRAF, PI3CA mutations, APC inactivation, ICRAS, TGF-beta, CTNNB mutations, disregulation of Epithelial to mesnechymal transition (EMT) genes, WNT signaling activation, MYC amplification, and others. Differences in these molecular events results in differences in phenotypic characteristics of CRC, that have been studied and classified by different models of molecular subtypes. It could have potential applications to prognosis, but also to therapeutical approaches of the CRC patients. We review and summarized the different molecular classifications and try to clarify their clinical and therapeutical relevance. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：9 / 19

页数：11

共 92 条

[1] Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [J].

Andre, Thierry ;

de Gramont, Armand ;

Vernerey, Dewi ;

Chibaudel, Benoist ;

Bonnetain, Franck ;

Tijeras-Raballand, Annemilai ;

Scriva, Aurelie ;

Hickish, Tamas ;

Tabernero, Josep ;

Van Laethem, Jean Luc ;

Banzi, Maria ;

Maartense, Eduard ;

Shmueli, Einat ;

Carlsson, Goran U. ;

Scheithauer, Werner ;

Papamichael, Demetris ;

Moeehler, Marcus ;

Landolfi, Stefania ;

Demetter, Pieter ;

Colote, Soudhir ;

Tournigand, Christophe ;

Louvet, Christophe ;

Duval, Alex ;

Flejou, Jean-Francois ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) :4176-+

[2]

[Anonymous], ASCO M ABSTRACTS S

[3]

[Anonymous], EUR J CANC

[4]

[Anonymous], LANCET

[5]

[Anonymous], 2014, ANN ONCOL

[6] Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory [J].

Arnold, Melina ;

Karim-Kos, Henrike E. ;

Coebergh, Jan Willem ;

Byrnes, Graham ;

Antilla, Ahti ;

Ferlay, Jacques ;

Renehan, Andrew G. ;

Forman, David ;

Soerjomataram, Isabelle .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (09) :1164-1187

[7] FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation [J].

Babaei-Jadidi, Roya ;

Li, Ningning ;

Saadeddin, Anas ;

Spencer-Dene, Bradley ;

Jandke, Anett ;

Muhammad, Belal ;

Ibrahim, ElSayed E. ;

Muraleedharan, Ranjithmenon ;

Abuzinadah, Mohammed ;

Davis, Hayley ;

Lewis, Annabelle ;

Watson, Susan ;

Behrens, Axel ;

Tomlinson, Ian ;

Nateri, Abdolrahman Shams .

JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (02) :295-312

[8] CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].

BAKER, SJ ;

FEARON, ER ;

NIGRO, JM ;

HAMILTON, SR ;

PREISINGER, AC ;

JESSUP, JM ;

VANTUINEN, P ;

LEDBETTER, DH ;

BARKER, DF ;

NAKAMURA, Y ;

WHITE, R ;

VOGELSTEIN, B .

SCIENCE, 1989, 244 (4901) :217-221

[9] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].

Barbie, David A. ;

Tamayo, Pablo ;

Boehm, Jesse S. ;

Kim, So Young ;

Moody, Susan E. ;

Dunn, Ian F. ;

Schinzel, Anna C. ;

Sandy, Peter ;

Meylan, Etienne ;

Scholl, Claudia ;

Froehling, Stefan ;

Chan, Edmond M. ;

Sos, Martin L. ;

Michel, Kathrin ;

Mermel, Craig ;

Silver, Serena J. ;

Weir, Barbara A. ;

Reiling, Jan H. ;

Sheng, Qing ;

Gupta, Piyush B. ;

Wadlow, Raymond C. ;

Le, Hanh ;

Hoersch, Sebastian ;

Wittner, Ben S. ;

Ramaswamy, Sridhar ;

Livingston, David M. ;

Sabatini, David M. ;

Meyerson, Matthew ;

Thomas, Roman K. ;

Lander, Eric S. ;

Mesirov, Jill P. ;

Root, David E. ;

Gilliland, D. Gary ;

Jacks, Tyler ;

Hahn, William C. .

NATURE, 2009, 462 (7269) :108-U122

[10] Tumor karyotype predicts clinical outcome in colorectal cancer patients [J].

Bardi, G ;

Fenger, C ;

Johansson, B ;

Mitelman, F ;

Heim, S .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2623-2634

← 1 2 3 4 5 6 7 8 9 10 →